BioCentury
ARTICLE | Company News

LabCorp, NanoString sales and marketing update

January 20, 2014 8:00 AM UTC

LabCorp launched NanoString's Prosigna Breast Cancer Prognostic Gene Signature Assay in the U.S. for use as a prognostic indicator for distant recurrence-free survival at 10 years. The breast cancer intrinsic subtyping assay is indicated in postmenopausal women with stage I/II lymph node-negative or stage II lymph node-positive hormone receptor-positive breast cancer who have undergone surgery in conjunction with locoregional treatment consistent with standard of care. The product, which has CE Mark approval and is available in Europe and Israel, runs on the nCounter Analysis System and uses the PAM50 gene signature. LabCorp could not be reached for details (see BioCentury, Feb. 25, 2013 & Sept. 16, 2013). ...